Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05077800 · ClinicalTrials.gov registry record · Phase 2
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
A Phase 2 study of Pancreatic Adenocarcinoma and Pancreatic Adenocarcinoma Metastatic, sponsored by Colin D. Weekes, M.D., PhD.
- Active
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 4
- Study locations
NCT05077800: Active Phase 2 study of Pancreatic Adenocarcinoma and Pancreatic Adenocarcinoma Metastatic, sponsored by Colin D. Weekes, M.D., PhD.
NCT05077800 is a Phase 2 study of Pancreatic Adenocarcinoma and Pancreatic Adenocarcinoma Metastatic that is active but no longer recruiting, run by Colin D. Weekes, M.D., PhD. The registered enrollment target is 70 participants, below the 99,464-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05077800, a Phase 2 study of Pancreatic Adenocarcinoma and Pancreatic Adenocarcinoma Metastatic, is active but no longer recruiting, sponsored by Colin D. Weekes, M.D., PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant to standard treatment for the disease. The names of the study drugs involved in this study are: * 9-ING-41 * Losartan * Ferumoxytol * FOLFIRINOX (made up of 4 different drugs): * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin
Primary Outcome
Defined from the date of study entry to the earliest date of progressive disease while receiving complete therapy with FOLFIRINOX-based therapy or death due to any cause. PFS will be censored at the date of last follow-up for patients alive without documented progression. PFS curves will be estimated by the Kaplan-Meier method and compared to historical controls treated with FOLFIRINOX alone using the one-sample log-rank test.
Conditions Studied
Interventions
- DRUG Losartan
- DRUG 9-ING-41
- DRUG FOLFIRNINOX
Study Locations (4)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Massachusetts General Hospital - Charlestown
Colorado
- University of Colorado Cancer Center - Aurora
Washington
- University of Washington School of Medicine - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
What the registry record for NCT05077800 still lists
NCT05077800 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 99,464-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Losartan is the first listed.
NCT05077800 reports a single indexed study location in Massachusetts, Colorado, Washington.
Frequently Asked Questions
What is clinical trial NCT05077800 about?
NCT05077800 is a clinical study titled "FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer". The purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant to standard treatment for the disease. The names of the study drugs involved in this study are: * 9-ING-41 * Losartan * Ferumoxytol * FOLFIRINOX (made up of 4 ...
What is the current status of trial NCT05077800?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2022-03-21. Estimated completion is 2026-07-31.
What conditions does trial NCT05077800 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic.
What interventions are being tested in trial NCT05077800?
The interventions under investigation include: Losartan (DRUG), 9-ING-41 (DRUG), FOLFIRNINOX (DRUG).
Who is sponsoring clinical trial NCT05077800?
This trial is sponsored by Colin D. Weekes, M.D., PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05077800 being conducted?
This trial has 4 study locations across Colorado, Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05077800's enrollment target sits among peer trials
70 31st of 62 higher than 32 of 62 other Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
RECRUITING · Phase 2
-
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
RECRUITING · Phase 2
-
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI